And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is a busy, if unexciting, one — we plan to spend much of our time tidying up around the castle and manicuring the official grounds. And what about you? This is a lovely time of year to enjoy the great outdoors. You could catch up on your reading, or napping, if you prefer. Or perhaps reach out to someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …
AstraZeneca suffered a notable shareholder rebellion over compensation for its chief executive and chief financial officer, the Wall Street Journal tells us. Almost 39 percent of shareholders at the annual meeting on Thursday voted against loosening requirements for distributing a share award that was proposed by the company’s remuneration committee. Institutional Shareholder Services, a group that advises investors, opposed the change.
About the Author Reprints
Interesting quote re Lupin from the article: ““These observations do not look very serious in nature and Lupin should be able to resolve them within one or two quarters…” The ‘numbers’ in the 483 show something different but “you decide” – this link opens a pdf rather than a page. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/CDERFOIAElectronicReadingRoom/UCM555428.pdf